Bogotá Political Weekly
SEE OTHER BRANDS

Your best source on politics and government news from Colombia

Trump Announces End of US Aid, New Tariffs on Colombia

(MENAFN) US President Donald Trump declared on Sunday that his administration will halt all financial assistance to Colombia and implement tariffs on the South American nation.

He accused the Colombian government of neglecting efforts to combat drug manufacturing and labeled its president, Gustavo Petro, as “a lunatic.”

Upon his arrival in Washington, Trump spoke to reporters and confirmed that Senator Lindsey Graham’s earlier statement regarding upcoming tariffs on Colombia was “correct.”

The specific tariff rates were set to be revealed on Monday.

“I’m stopping all payments to Colombia because they don’t have anything to do with their fight against drugs,” Trump stated.

He further accused Colombia of being deeply involved in the drug trade, saying, “They make drugs, they refine drugs, they make cocaine. They have no fight against drugs. Colombia is out of control, and now they have the worst president they’ve ever had. He’s a lunatic who’s got a lot of problems, mental problems.”

Trump also criticized Colombia for the global impact of its drug exports, stating the country “destroys families” by distributing cocaine worldwide.

He insisted that Colombia “has no intention” of reducing drug production.

MENAFN20102025000045017167ID1110218915


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions